We are conducting trade talks on the next foreign market – Israel. It is consistent with our strategy of quantitative growth of markets and their diversification.
This year, in January, testing of Pregnabit teleCTG devices with a potential partner in Israel has started. Tests will last two months. They were preceded by meetings with medical experts at two clinics and a hospital in Tel Aviv. At the same time, the local partner is conducting intensive activities aimed at interest in the Pregnabit system of four health insurance funds operating on the Israeli market and finding an effective way to enter the Pregnabit teleCTG into the pregnant care system in Israel.
Israel has one of the world’s best healthcare systems. The government of the country declares that it has ambitions to become a global leader in the field of health care. Hence the huge openness to new technologies in the care of the patient. In Israel, the fertility rate in 2018 amounted to 2.95 and 170 000 children are born there annually. Because of that, there is a great interest in modern care of a pregnant patient.
Israel is very open to innovations that make it possible to increase the standard of perinatal care. It is also known as one of the largest start-up areas of the world and the emergence of new technologies. We believe that we will also find a business space there for our technology, the more so as we cooperate with a partner with extensive experience in launching innovative medical solutions on the market – emphasizes Patrycja Wizińska – Socha, President of Nestmedic S.A.